Back to UBS Group AG UBS Group AG

PTGXPTGX
29 quarters

Position history for UBS Group AGUBS Group AG's holdings in PROTAGONIST THERAPEUTICS INC

UBS Group AG holds 5.2M shares of PTGX (PROTAGONIST THERAPEUTICS INC), worth $545.7M as of 2026-Q1. The position was increased (+86.9% shares). PTGX represents 0.1% of UBS Group AG's portfolio.

Current Value

$545.7M

Current Shares

5.2M

Total Value Change

+$545.7M

Total Shares Change

+5.2M

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q1
Latest
Increased
5.2M
+86.9%
$545.7M0.1%$91.30
49
2025-Q4
Increased
2.8M
+46.1%
$241.9M0.0%$87.26
42
2025-Q3
Decreased
1.9M
-24.2%
$126M0.0%$65.14
0
2025-Q2
Increased
2.5M
+608.8%
$138.2M0.0%$55.69
49
2025-Q1
Increased
352,871
+166.1%
$17.1M0.0%$48.88
46
2024-Q4
Increased
132,609
+68.3%
$5.1M0.0%$38.51
40
2024-Q3
Increased
78,799
+17.6%
$3.5M0.0%$44.56
31
2024-Q2
Decreased
66,981
-62.3%
$2.3M0.0%$34.65
0
2024-Q1
Increased
177,546
+17.7%
$5.1M0.0%$28.93
32
2023-Q4
Increased
150,867
+66.3%
$3.5M0.0%$22.93
39
2023-Q3
Increased
90,726
+38.4%
$1.5M0.0%$16.68
34
2023-Q2
Decreased
65,540
-43.5%
$1.8M0.0%$27.67
0
2023-Q1
Decreased
115,939
-48.6%
$2.7M0.0%$22.49
0
2022-Q4
Increased
225,529
+384.2%
$2.5M0.0%$10.91
42
2022-Q3
Decreased
46,580
-63.9%
$393,0000.0%$8.25
0
2022-Q2
Increased
128,987
+5.1%
$1M0.0%$8.07
26
2022-Q1
Increased
122,765
+85.1%
$2.9M0.0%$23.92
41
2021-Q4
Decreased
66,311
-4.2%
$2.3M0.0%$34.25
0
2021-Q3
Increased
69,215
+2491.3%
$1.2M0.0%$17.57
41
2021-Q2
Decreased
2,671
-94.0%
$120,0000.0%$44.10
0
2021-Q1
Decreased
44,573
-31.4%
$1.2M0.0%$25.31
0
2020-Q4
Increased
64,933
+19.2%
$1.3M0.0%$19.99
30
2020-Q3
Decreased
54,488
-20.7%
$1.1M0.0%$20.25
0
2020-Q2
Decreased
68,687
-6.2%
$1.2M0.0%$17.39
0
2020-Q1
Increased
73,233
+246.1%
$517,0000.0%$7.17
39
2019-Q4
Increased
21,159
+27.3%
$149,0000.0%$7.16
28
2019-Q3
Decreased
16,619
-84.0%
$200,0000.0%$13.15
0
2019-Q2
Increased
104,201
+6234.4%
$1.3M0.0%$12.11
41
2019-Q1
New
1,645
-
$21,0000.0%$12.57
29

Other major holders of PTGX: BlackRock, Inc., FARALLON CAPITAL MANAGEMENT, L.L.C.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used